Anson K Wurapa

Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV

Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh et al. · AIDS · 2021 · 64 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study

Debbie Hagins, Princy Kumar, Michael S. Saag et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2021 · 44 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial

Joseph J. Eron, Jean‐Daniel Lelièvre, Robert C. Kalayjian et al. · The Lancet HIV · 2018 · 33 citations

Pharmacy, Nephrology, Pharmacotherapy +17

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks

Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh et al. · Open Forum Infectious Diseases · 2023 · 24 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Oral Hairy Leukoplakia: A Manifestation of Primary Infection with Epstein-Barr Virus?

Anson K Wurapa · Scandinavian Journal of Infectious Diseases · 1999 · 14 citations

Dentistry, Dermatology, Immunology +17